IVIrina Velikyan

Irina Velikyan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Irina Velikyan has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Theranostics at its best: clinical breast cancer imaging and quantification targeting HER2 receptors

    by Irina Velikyan, Anders Wennborg, Joachim Frldwisch, Helena Olofsson, Dan Sandberg, Mark Lubberink, Mattias Sandstrom, Henrik Lindman, Jorgen Carlsson, Jens Sorensen

    The currently best known example of a commercialized theranostics is the combination of HercepTest and Herceptin wherein the former is used for HER2 expression assessment and selection of patients that might benefit from the treatment with the latter. However, HercepTest requires biopsy which is an invasive procedure, not sufficiently accurate, and very difficult to perform on several lesions and repeatedly in order to monitor the treatment response. While positron emission tomography (PET) in combination with HER2 targeting radiopharmaceutical provides quantitative whole body examination which accuracy is high and independent on heterogeneity of receptor expression. PET imaging agent, [68Ga]Ga-ABY-025, was produced in compliance with GMP and GRPP in two peptide doses. The peptide Affibody molecule, ABY-025, was provided by Affibody AB. 68Ga was obtained from a 68Ge/68Ga-generator (IGG100, Eckert & Ziegler). Patients with diagnosed metastatic breast cancer were enrolled. Two PET/CT examinations with low and high peptide content radiopharmaceuticals were performed for each patient. The examination started with dynamic acquisition (0–45 min) followed by three static runs at 1, 2 and 4 h post injection. Immunohistochemistry (IHC) on the metastasis biopsies were performed for HER2 expression verification. The study was approved by the Swedish Medical Products Agency (EudraCT 2012-005228-14, NCT01858116) and the Regional Board of Medical Ethics. The examination using radiopharmaceutical with high peptide content resulted in higher contrast images with lower uptake in healthy organs such as liver. The contrast increased with the time however already 2 h post injection was found optimum for routine use. SUVs correlated with IHC HER2-scores. Based on [68Ga]Ga-ABY-025/PET-CT, the treatment was changed in 19% of the patients. [68Ga]Ga-ABY-025/PET-CT demonstrated strong potential to improve patient management efficacy by providing pre-therapeutic accurate whole body determination of HER2 expression extent and treatment response monitoring with minimal patient discomfort.


  • Imaging biomarkers for diagnosis and quantification with positron emission tomography: assistance to therapy

    by Irina Velikyan, Anders Sundin, Barbro Eriksson, Hans Lundqvist, Jens Sörensen, Mats Bergström, Bengt Långström

    • 1 February 2004
      • Vol. 45  (2) , 347-55

    68Ga-labeled oligonucleotides for in vivo imaging with PET.

    by Anne Roivainen, Tuula Tolvanen, Satu Salomäki, Gabor Lendvai, Irina Velikyan, Petri Numminen, Maria Välilä, Hannu Sipilä, Mats Bergström, Pirkko Härkönen, et al.

    The biologic evaluation in living rats of (68)Ga-labeled oligonucleotides as imaging agents for PET is reported. (68)Ga, a positron-emitting radionuclide (half-life, 68 min), along with a macrocyclic chelating agent, 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA), was used for labeling of antisense oligonucleotides targeting activated human K-ras oncogene. The biologic properties of 3 different forms of the oligonucleotides-that is, 2'-deoxyphosphodiester (PO), 2'-deoxyphosphorothioate (PS), and 2'-O-methyl phosphodiester (OMe)-were studied first. The biodistribution and biokinetics were evaluated in vivo in athymic rats, each bearing a tumor of A549 cells, containing K-ras point mutation in codon 12, and a tumor of BxPC-3 cells, containing wild-type K-ras. Dynamic PET imaging lasting up to 2 h was performed immediately after intravenous injection of (68)Ga-oligonucleotide. Blank studies were performed using (68)GaCl(3) or (68)Ga-DOTA alone without oligonucleotide. The (68)Ga-antisense oligonucleotide uptake in tumors was also compared with the (18)F-FDG and (68)Ga-sense oligonucleotide uptakes. In addition, oligonucleotide binding to human plasma proteins and to human albumin was examined by means of ultrafiltration. The oligonucleotides can be stably labeled with (68)Ga and DOTA chelate. Intravenously injected (68)Ga-oligonucleotides of 17-mer length revealed high-quality PET images, allowing quantification of the biokinetics in major organs and in tumors. The biodistribution and biokinetics of intravenously administered (68)Ga-oligonucleotide varied considerably with the nature of the oligonucleotide backbone. We conclude that (68)Ga labeling of oligonucleotides is a convenient approach for in vivo imaging and quantification of oligonucleotide biokinetics in living animals with PET.